Current concepts in the treatment of chronic myelocytic leukemia.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001791:Blood Platelet Disorders / Q000139:chemically induced; D001966:Bromine / Q000627:therapeutic use; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004376:Galactitol / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007167:Immunotherapy; D007951:Leukemia, Myeloid / Q000150:complications / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008353:Mannitol / Q000627:therapeutic use; D015122:Mercaptopurine / Q000627:therapeutic use; D013156:Splenectomy; D014499:Uracil Mustard / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004376:Galactitol; D008353:Mannitol; D015122:Mercaptopurine; D002066:Busulfan; D001966:Bromine; D014499:Uracil Mustard; D006918:Hydroxyurea